These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22245538)

  • 1. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
    Martins S; Tho I; Souto E; Ferreira D; Brandl M
    Eur J Pharm Sci; 2012 Apr; 45(5):613-23. PubMed ID: 22245538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition.
    Martins S; Tho I; Ferreira DC; Souto EB; Brandl M
    Drug Dev Ind Pharm; 2011 Jul; 37(7):815-24. PubMed ID: 21214488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy.
    Mukherjee S; Ray S; Thakur RS
    Pak J Pharm Sci; 2009 Apr; 22(2):131-8. PubMed ID: 19339221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
    Teeranachaideekul V; Müller RH; Junyaprasert VB
    Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.
    Gonzalez-Mira E; Egea MA; Garcia ML; Souto EB
    Colloids Surf B Biointerfaces; 2010 Dec; 81(2):412-21. PubMed ID: 20719479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size.
    Ghadiri M; Fatemi S; Vatanara A; Doroud D; Najafabadi AR; Darabi M; Rahimi AA
    Int J Pharm; 2012 Mar; 424(1-2):128-37. PubMed ID: 22227603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil.
    Averina ES; Seewald G; Müller RH; Radnaeva LD; Popov DV
    Pharmazie; 2010 Jan; 65(1):25-31. PubMed ID: 20187575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of surfactant properties on oxidative stability of beta-carotene encapsulated within solid lipid nanoparticles.
    Helgason T; Awad TS; Kristbergsson K; Decker EA; McClements DJ; Weiss J
    J Agric Food Chem; 2009 Sep; 57(17):8033-40. PubMed ID: 19691283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis.
    Lopes R; Eleutério CV; Gonçalves LM; Cruz ME; Almeida AJ
    Eur J Pharm Sci; 2012 Mar; 45(4):442-50. PubMed ID: 21983568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of miscibility and polymorphism of synthetic and natural lipids for nanostructured lipid carrier (NLC) formulations by Raman mapping and multivariate curve resolution (MCR).
    Mitsutake H; Ribeiro LNM; Rodrigues da Silva GH; Castro SR; de Paula E; Poppi RJ; Breitkreitz MC
    Eur J Pharm Sci; 2019 Jul; 135():51-59. PubMed ID: 31071439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
    Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
    Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies.
    Martins S; Tho I; Reimold I; Fricker G; Souto E; Ferreira D; Brandl M
    Int J Pharm; 2012 Dec; 439(1-2):49-62. PubMed ID: 23046667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
    Liu CH; Wu CT; Fang JY
    Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key production parameters for the development of solid lipid nanoparticles by high shear homogenization.
    Souto EB; Doktorovova S; Zielinska A; Silva AM
    Pharm Dev Technol; 2019 Nov; 24(9):1181-1185. PubMed ID: 31354002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of solid lipid nanoparticles (SLN): the value of different alkyl polyglucoside surfactants.
    Keck CM; Kovačević A; Müller RH; Savić S; Vuleta G; Milić J
    Int J Pharm; 2014 Oct; 474(1-2):33-41. PubMed ID: 25108048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
    Heider M; Hause G; Mäder K
    Eur J Pharm Biopharm; 2016 Dec; 109():194-205. PubMed ID: 27789354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
    Attama AA; Müller-Goymann CC
    Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN).
    Helgason T; Awad TS; Kristbergsson K; McClements DJ; Weiss J
    J Colloid Interface Sci; 2009 Jun; 334(1):75-81. PubMed ID: 19380149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.